Prospect: information for the patient
Bixcar 800 mg tablets EFG
eslicarbazepine acetate
Read this prospect carefully before starting to take this medication, as it contains important information for you.
Bixcar contains the active ingredient acetate of eslicarbazepine.
Eslicarbazepine belongs to a group of medications called antiepileptics, used to treat epilepsy, a disease where the affected person has seizures or repeated convulsive crises.
Eslicarbazepine is used:
Your doctor has prescribed eslicarbazepine to reduce the number of seizures.
Warnings and precautions
Consult your doctor or pharmacist before starting to take eslicarbazepine.
Inform your doctor immediately:
Inform your doctor:
A small number of people taking antiepileptic medications have had thoughts of self-harm or suicide. If this occurs while taking eslicarbazepine, contact your doctor immediately.
Eslicarbazepine may cause dizziness and/or drowsiness, particularly at the start of treatment. Be extra careful while taking eslicarbazepine to avoid accidental injuries, such as falls.
Be extra careful with eslicarbazepine
In the post-marketing experience, severe skin reactions and potentially life-threatening reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported in patients treated with eslicarbazepine.
If you develop a severe rash or other skin symptoms (see section 4), stop taking eslicarbazepine and consult your doctor or seek medical attention immediately.
In patients of Thai and Chinese Han ethnic origin, the risk of severe skin reactions associated with carbamazepine or chemically related compounds may be predicted by blood analysis. Your doctor will advise on the need for this blood test before taking eslicarbazepine.
Children
Eslicarbazepine should not be administered to children under 6 years of age.
Other medications and Bixcar
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. This is to ensure that none of them interfere with the way eslicarbazepine works, or that eslicarbazepine interferes with the effect of such medications. Inform your doctor if you are taking:
See the section “Pregnancy and breastfeeding” for recommendations on contraception.
Pregnancy and breastfeeding
Acetate of eslicarbazepine is not recommended for use during pregnancy, as its effects on pregnancy and the fetus are unknown.
If you intend to become pregnant, discuss this with your doctor before stopping your contraceptive method and before becoming pregnant. Your doctor may decide to change your treatment.
There is limited data on the use of acetate of eslicarbazepine in pregnant women.
Research has shown an increased risk of congenital defects and neurological development problems (brain development) in the children of women taking antiepileptic medications, particularly when taking more than one antiepileptic medication at a time.
If you are or think you may be pregnant, inform your doctor immediately. Do not stop taking your medication until you have discussed this with your doctor. Stopping your medication without consulting your doctor may cause seizures, which can be dangerous for you and your unborn child. Your doctor may decide to change your treatment.
If you are a fertile woman and are not planning to become pregnant, you should use an effective contraceptive method during treatment with acetate of eslicarbazepine. Acetate of eslicarbazepine may affect the functioning of hormonal contraceptives, such as the birth control pill, and make them less effective for preventing pregnancy.
Therefore, it is recommended to use other safe and effective forms of contraception while taking acetate of eslicarbazepine. Discuss this with your doctor, who will advise on the most suitable type of contraceptive to use while taking acetate of eslicarbazepine. If you stop treatment with acetate of eslicarbazepine, continue using an effective contraceptive method until the end of the current menstrual cycle. If you take acetate of eslicarbazepine during pregnancy, your baby may also be at risk of bleeding problems immediately after birth. Your doctor may give you and your baby a medication to prevent this.
Do not breastfeed while taking acetate of eslicarbazepine. It is unknown whether it passes into breast milk.
Driving and operating machinery
Eslicarbazepine may cause symptoms such as drowsiness, dizziness, or visual disturbances, and may impair your ability to react. These effects, as well as the underlying disease, may make it difficult for you to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or engage in other activities that require special attention, until your doctor assesses your response to this medication.
This medication contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Adults
Initial treatment dose
400 mg once a day for one or two weeks, before increasing to the maintenance dose. Your doctor will decide if you should take this dose for one or two weeks.
Maintenance dose
The usual maintenance dose is 800 mg once a day.
Depending on how you respond to eslicarbazepine, the dose may be increased to 1,200 mg once a day. If you are taking eslicarbazepine alone (monotherapy), your doctor may consider increasing your dose to 1,600 mg once a day.
Patients with kidney problems
If you have kidney problems, you will usually be given a lower dose of eslicarbazepine. Your doctor will determine the correct dose for you. Eslicarbazepine is not recommended if you have severe kidney problems.
Older adults (65 years and older)
If you are an older adult and taking eslicarbazepine as monotherapy, the dose of 1,600 mg is not suitable for you.
Children over 6 years of age
Initial treatment dose
The initial dose is 10 mg per kg of body weight once a day for one or two weeks, before increasing to the maintenance dose.
Maintenance dose
Depending on your response to eslicarbazepine, the dose may be increased by 10 mg per kg of body weight, at intervals of one or two weeks, up to 30 mg per kg of body weight. The maximum dose is 1,200 mg once a day.
Children ≥ 60 kg
Children with a body weight of 60 kg or more should take the same dose as adults.
The oral suspension (other form not available for this medication) may be more suitable for administration in children. Consult your doctor or pharmacist.
Form and route of administration
Eslicarbazepine is administered orally. Swallow the tablet with a glass of water. Eslicarbazepine can be taken with or without food.
The tablet can be divided into equal doses.
If you take more Bixcar than you should
If you accidentally take more eslicarbazepine than you should, you are at risk of having more seizures; or you may feel that your heartbeat is irregular or faster. Contact your doctor or go immediately to a hospital if you experience any of these symptoms. Bring the medication packaging with you, so the doctor knows what you have taken.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Bixcar
If you forget to take a tablet, take it as soon as you remember and continue as usual. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Bixcar
Do not suddenly stop taking the tablets. If you do, you are at risk of having more seizures. Your doctor will decide for how long you should take eslicarbazepine. If your doctor decides to stop your treatment with eslicarbazepine, you will usually be gradually reduced the dose. It is essential that you complete the treatment as instructed by your doctor; otherwise, your symptoms may worsen.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
The following side effects can be very serious. If they occur, stop taking eslicarbazepine and inform your doctor or go to the hospital immediately, as you may need urgent medical treatment:
The side effectsvery common(can affect more than 1 in 10 people) are:
The side effectscommon(can affect up to 1 in 10 people) are:
The side effectsnot common(can affect up to 1 in 100 people) are:
The side effects ofunknown frequency(cannot be estimated from available data) are:
The use of eslicarbazepine is associated with an ECG anomaly called an increase in the PR interval. Side effects associated with this ECG anomaly may occur (for example, fainting and slowing of heartbeats).
Bone disorders including osteopenia and osteoporosis (bone thinning) and fractures have been reported with antiepileptic drugs related in structure to eslicarbazepine, such as carbamazepine and oxcarbazepine. Talk to your doctor or pharmacist if you are on long-term treatment with antiepileptics, have a history of osteoporosis, or take steroids.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be thrown down the drain or in the trash. Dispose of the packaging and the medicines you no longer need at the SIGRE drop-off point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and the medicines you no longer need. By doing so, you will help protect the environment.
Composition of Bixcar
Appearance of the product and contents of the packaging
Oblong, biconvex tablets, approximately 21 x 8.5 mm in size, scored on one face.The tablet can be divided into equal doses.
PVC-Aluminum blisters.
30 or 60 tablet packaging.
Marketing authorization holder and responsible manufacturer
Laboratorios Alter, S.A.
C/ Mateo Inurria 30
28036 Madrid
Spain
Last review date of this leaflet:
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.